Cooper Companies (NASDAQ:COO) Given New $107.00 Price Target at Robert W. Baird

Cooper Companies (NASDAQ:COO) had its price target lowered by Robert W. Baird from $117.00 to $107.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the medical device company’s stock. Robert W. Baird’s price target would suggest a potential upside of 17.61% from the stock’s previous close.

Other equities research analysts have also issued research reports about the company. Wells Fargo & Company boosted their price target on Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a report on Friday. Morgan Stanley lowered their target price on Cooper Companies from $104.00 to $102.00 and set an “equal weight” rating on the stock in a report on Friday, December 6th. Citigroup cut their price target on Cooper Companies from $115.00 to $110.00 and set a “buy” rating for the company in a report on Friday. Finally, StockNews.com downgraded Cooper Companies from a “buy” rating to a “hold” rating in a research report on Wednesday, December 11th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $114.67.

Cooper Companies Trading Down 0.4 %

Shares of COO stock opened at $90.98 on Friday. The company has a current ratio of 1.91, a quick ratio of 1.12 and a debt-to-equity ratio of 0.32. The stock has a market cap of $18.16 billion, a price-to-earnings ratio of 46.66, a PEG ratio of 2.25 and a beta of 1.02. The company’s 50-day moving average price is $92.56 and its 200-day moving average price is $99.51. Cooper Companies has a twelve month low of $84.76 and a twelve month high of $112.38.

Cooper Companies (NASDAQ:COO) last posted its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.92. The company had revenue of $964.70 million for the quarter, compared to analysts’ expectations of $981.25 million. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. As a group, equities analysts predict that Cooper Companies will post 3.98 earnings per share for the current year.

Institutional Trading of Cooper Companies

Hedge funds have recently made changes to their positions in the stock. Ashton Thomas Securities LLC acquired a new position in Cooper Companies during the 3rd quarter valued at about $25,000. Byrne Asset Management LLC purchased a new position in Cooper Companies in the 4th quarter worth about $33,000. OFI Invest Asset Management acquired a new stake in Cooper Companies during the 4th quarter valued at $34,000. Covestor Ltd lifted its position in shares of Cooper Companies by 144.9% in the third quarter. Covestor Ltd now owns 338 shares of the medical device company’s stock worth $37,000 after purchasing an additional 200 shares in the last quarter. Finally, New Age Alpha Advisors LLC purchased a new position in Cooper Companies in the fourth quarter valued at about $38,000. Institutional investors own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.